CHOOSE IXINITY®

Offer your patients predictable bleed control and an established safety profile

*Previously treated patients (PTPs) receiving routine prophylactic treatment of 40 IU/kg to 70 IU/kg of IXINITY twice weekly demonstrated a median annualized spontaneous bleeding rate (AsBR) of 0, and a median total annualized bleeding rate (ABR) of 1.52.2

The efficacy (n=68) and safety (n=77) of IXINITY have been evaluated in a prospective, open-label, uncontrolled, multicenter trial in which previously treated patients between 7 and 64 years of age received IXINITY in either a routine or on demand regimen, including 55 patients with more than 50 exposure days and 45 of those patients with more than 100 exposure days.2

*Previously treated patients (PTPs) receiving routine prophylactic treatment of 40 IU/kg to 70 IU/kg of IXINITY twice weekly demonstrated a median annualized spontaneous bleeding rate (AsBR) of 0, and a median total annualized bleeding rate (ABR) of 1.52.2

The efficacy (n=68) and safety (n=77) of IXINITY have been evaluated in a prospective, open-label, uncontrolled, multicenter trial in which previously treated patients between 7 and 64 years of age received IXINITY in either a routine or on demand regimen, including 55 patients with more than 50 exposure days and 45 of those patients with more than 100 exposure days.2

Connect with your local IXINITY Specialist and see if IXINITY is the right treatment for your patients.

Up to 20,000 IU.

Reference 1: Data on file. Chicago, IL: Medexus Pharma, Inc. 2. IXINITY [coagulation factor IX (recombinant)] prescribing information. Chicago, IL: Medexus Pharma, Inc.; February 2021.